Skip to Content

Cell/Gene Therapy & Tumor Immunology

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Position Description:

We are seeking a highly devoted and enthusiastic PhD or MD/PhD scientist to join our group as a post-doctoral research fellow. We recently identified mechanisms of response and resistance to chimeric antigen receptor (CAR) T cell therapy in leukemias 1. Our laboratory focuses on the functional fate mapping of CAR T cells using high-end single cell transcriptomics and proteomics approaches, combined with functional in vitro and in vivo mechanistic studies to further understand the long-term persistent memory CAR T cells and translate such findings into novel gene therapies for cancer.

We have a post-doctoral position open to support these efforts. This position will utilize next-generation single cell technologies to characterize and monitor chimeric antigen receptor (CAR) T cells from leukemia patients treated at our center with autologous CD19 CAR-redirected T cells. In addition, this position will study the biology of the CAR integration on the local, regional, and global gene activity in the modified T cells via gene editing technologies and deep mechanistic studies.

Qualifications:

Preferred: Experience in tumor immunology and immunotherapy, mass cytometry, flow cytometric purification of cell populations using the BD Aria, substantial expertise with human/murine T cell functional assays (especially high definition polychromatic flow cytometry), gene editing via CRISPR/Cas9, and tumor mouse models, scientific knowledge and research experience in human immunology with a track record of publication in peer-reviewed journals.

Basic: Ph.D. and/or M.D. in immunology or genetics. Must have research experience in the cellular and molecular aspects of tumor immunology. Able to work well in a highly dynamic, collaborative work environment.

To Apply:

Please forward a cover letter describing your career plans, updated CV with research statement and the names/contact information for 3 professional references to:

J. Joseph Melenhorst, PhD
Department of Pathology and Laboratory Medicine
Center for Cellular Immunotherapies
Perelman School of Medicine
University of Pennsylvania
E-mail: mej@upenn.edu

References

  1. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571. doi:10.1038/s41591-018-0010-1
  2. Fraietta JA, Nobles CL, Sammons MA, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. May 2018:1. doi:10.1038/s41586-018-0178-z
  3. Maus M V. Tumour tamed by transfer of one T cell. Nature. May 2018. doi:10.1038/d41586-018-05251-5